ClinicalTrials.gg
Not yet recruitingNCT07727629Updated Jul 27, 2026

Safety, PK, and PD Comparison of UI059 and UIC202201 in Healthy Volunteers

A Phase 1 interventional study of UI059 and UIC202201 in Gastro Esophageal Reflux Disorder, sponsored by Korea United Pharm. Inc.. Not yet recruiting at 1 site in South Korea. Open to participants aged 19 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-27.

Sponsored by Korea United Pharm. Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Aug 2026, 3 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 71 studies in Gastroesophageal Reflux with a site in Korea, Republic of — 8 open to participants now, 10 under way, none of them phase 3. Gastroesophageal Reflux · Korea, Republic of.

Planned enrollment
26th of 52
60 · median 54
Started
2026
with 1 other
Phase 1
21 of 71
2 open now
Registered
65th of 71
by date
Lead sponsor
3 of 71
Korea United Pharm. Inc.

Among the 71 studies in Gastroesophageal Reflux with a site in Korea, Republic of, this one is the 26th largest by planned enrollment of the 52 interventional ones that give a count, is one of 2 that started in 2026, is one of 21 in phase 1, and was the 65th registered.

Gastroesophageal Reflux

1,215 studies on the registry are indexed under Gastroesophageal Reflux; 203 are open to participants now.

Browse Gastroesophageal Reflux studies →

Open to participants now

8 of the 71 studies in Gastroesophageal Reflux with a site in Korea, Republic of are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 133 Gastroesophageal Reflux studies recruiting now, 57 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.

This study: 19 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 71 studies in Gastroesophageal Reflux with a site in Korea, Republic of, or all of them as a file.
02

Study summary

A randomized, open-label, multiple-dose, crossover phase 1 clinical trial to compare and evaluate the safety, pharmacokinetics and pharmacodynamics characteristics after oral administration of UI059 and UIC202201 in healthy adult volunteers

03

Conditions studied

  • Gastro Esophageal Reflux Disorder
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adult volunteers aged 19 years or older at the time of screening.
  • Weight and (BMI) at screening as follows:

    • Body weight: ≥50.0kg for males, ≥45.0kg for females.
    • BMI: ≥18.0mg/m2 and ≤ 30.0kg/m2
  • Subjects who do not have congenital or chronic diseases requiring treatment and have no pathological symptoms or findings based on medical examination.
  • Subjects judged suitable for the clinical trial based on laboratory tests, vital signs, physical examination, and 12-lead conducted at screening.
  • Subjects who test negative for H.pylori antibody at screening.
  • Subjects who voluntarily decide to participate and provide written after being fully informed of and understanding the details of this clinical trial and the subject compliance requirements.

Exclusion criteria

Exclusion Criteria:

  • Current or past history of liver, kidney, neurological, psychiatric, respiratory, endocrine, hematologic, oncologic, genitourinary, cardiovascular, gastrointestinal, or musculoskeletal diseases.
  • History of gastrointestinal diseases (e.g., Crohn's disease, ulcers, acute or chronic pancreatitis) or gastrointestinal surgery (excluding simple appendectomy, hernia repair, or dental procedures) that may affect the absorption of the product.
  • Pregnant (positive Urine-HCG test) or breastfeeding women.
  • History of clinically significant (e.g., anaphylaxis or angioedema) to the investigational product ingredients, , or other drugs (e.g., aspirin, penicillin-type antibiotics, macrolide antibiotics, etc.).
  • Clinically significant findings on 12-lead at screening, including:

    • >450ms(males) or >470ms(females)
    • PR intervals>200ms
    • QRS duration>120ms
  • Clinically significant laboratory results at screening, including:

    • Liver function (, ALT, ALP, γ-GT, and total ) exceeding 2 times the (ULN).
    • Serum creatinine outside the reference range, or calculated by the CKD-EPI formula \< 60 mL/min/1.73m2.
  • History of drug abuse or a positive response to drugs of abuse in the urine drug screen.
  • Vital signs measured in a sitting position after at least 3 minutes of rest at screening:

    • Systolic Blood Pressure ≤ 90 mmHg or ≥ 150 mmHg
    • Diastolic Blood Pressure ≤ 60 mmHg or ≥ 100 mmHg
    • Pulse Rate ≤ 40 bpm or ≥ 100 bpm
  • Abnormal diet or consumption of food that may affect the absorption, distribution, metabolism, and excretion (ADME) of the investigational product.
  • Use of any prescription drugs or herbal medicines within 2 weeks, or any over-the-counter (OTC) drugs or health functional foods within 10 days before the first dose (unless deemed by the investigator not to affect the PK of the investigational product).
  • Use of drugs that induce or inhibit drug-metabolizing enzymes (e.g., barbiturates) within 1 month before the first dose.
  • Participation and dosing in another clinical trial within 6 months before the first dose.
  • Whole blood donation within 2 months, component donation within 1 month, or blood transfusion within 1 month before the first dose; or inability to refrain from donation during the study.
  • Consistent alcohol consumption exceeding 21 units/week (1 unit = 10g of pure alcohol) within 6 months before the first dose, or inability to abstain from alcohol during the study.
  • Smokers who averaged > 10 cigarettes/day within 3 months before the first dose, or inability to quit smoking from 48 hours before the first dose until the last PK blood collection.
  • Consumption of food containing grapefruit within 72 hours before the first dose, or inability to abstain during the study.
  • Consumption of food containing caffeine (coffee, tea, soda, etc.) from 48 hours before each first dose until the last PK blood collection, or inability to abstain.
  • Strenuous exercise exceeding normal daily activities within 72 hours before the first dose, or inability to refrain from such exercise.
  • Subjects (or their partners) planning pregnancy, or those not using medically accepted methods of (e.g., hormonal contraceptives, IUD, sterilization, barrier methods) from the time of consent until 2 weeks after the last dose.
  • Any other reason the investigator deems the subject unsuitable for participation in the clinical trial.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    UI059

    Drug: UI059

  • Active comparator
    UIC202201

    Drug: UIC202201

Interventions

  • DrugUI059

    take UI059 once a day for 7 days

  • DrugUIC202201

    take UIC202201 once a day for 7 days

06

What researchers measure

Primary outcomes

  1. AUCτ,ss

    Time frame: day1: 0-24 hours / day 5, day 6: 0 hour / day 7: 0-24 hours

  2. Percent decrease from baseline in integrated gastric acidity

    Time frame: Day -1(0 hour) - Day 1(0 hour) / Day1(0 hour) - Day2(0 hour) / Day7(0 hour) - Day7(24 hour)

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2026; primary completion for Aug 2026, 1 month later.

Of 28 industry-sponsored phase 1 interventional studies under Gastroesophageal Reflux, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 6. This study's planned 1 month is below that.

Counting every sponsor, half of 34 studies reached it within 4 months; a quarter within 2 and three quarters within 10.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2026
First posted
Jul 27, 2026
StartEst.
Jul 2026
Primary completionEst.
Aug 2026
CompletionEst.
Aug 2026
Last update
Jul 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07727629
Responsible party
Sponsor
First posted
Jul 27, 2026
Start date
Jul 2026 (estimated)
Primary completion
Aug 2026 (estimated)
Completion
Aug 2026 (estimated)
Last update
Jul 27, 2026

Study contacts

Minkyu Park, MD, PhD
Contact
mk_park@cbnuhctc.com
+82432698708
Minkyu Park, MD, PhD
principal investigator · Chungbuk National University Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: UI059

Start the discussion